GSK sees further US job losses following Novartis deal
April 17, 2015Research and Development, Sales and Marketing GSK, Jobs, Novartis, cuts, merger, pittsburgh, restructuring
Hundreds more jobs are at risk within GlaxoSmithKline as the fallout from the company’s asset-swapping deal with Novartis continues. Staff …
AstraZeneca bags another FDA orphan status in cancer
April 17, 2015Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib
The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …
FDA approves generic Copaxone for multiple sclerosis
April 17, 2015Sales and Marketing FDA, Sandoz, Teva, glatiramer acetate injection, glatopa
The FDA has signed-off on the first generic version of Copaxone to treat people with relapsing forms of multiple sclerosis …
Merck chief executive replaces Pfizer boss as PhRMA chairman
April 17, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing George Scangos, Ian Read, Joaquin Duato, Kenneth Frazier, PhRMA
Chairman and chief executive of Merck Kenneth Frazier is to replace Pfizer boss Ian Read as chairman at the Pharmaceutical …
Merck Serono gains head of global clinical development
April 17, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alise Reicin, Merck, Merck Serono
Merck Serono, the biopharma business of Merck, has appointed Dr Alise Reicin as senior vice president and head of its …
AstraZeneca signs immuno-oncology deal with UK firm
April 16, 2015Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …
FDA approves Amgen’s heart failure drug
April 16, 2015Sales and Marketing Amgen, Corlanor, FDA, NICE, Vectibix, heart, ivabradine
Amgen has earned sign-off from the FDA for Corlanor as a treatment for people with worsening heart failure symptoms. Corlanor …
AbbVie hep C drug gets priority review in Japan
April 16, 2015Sales and Marketing AbbVie, EC, EU, Europe, Exviera, FDA, Japan, Viekira Pak, Viekirax, hepatitis C, ombitasvir/paritaprevir/ritonavir
AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …
Sun Pharma and Technion form oncology research pact
April 16, 2015Research and Development, Sales and Marketing Cancer, Sun Pharma, institute of technology, oncology, technion
Mumbai-based Sun Pharmaceuticals Industries is teaming up with the Israel Institute of Technology Technion to develop new oncology drugs. This …
New managing director for PM Devereux
April 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Julian Seward, PM Devereux
Healthcare, science and technology architectural firm PM Devereux has confirmed the appointment of Julian Seward as a managing director. Seward …
Pfizer breast cancer trial stopped following promising results
April 15, 2015Sales and Marketing ASCO, FDA, Pfizer, ibrance, palbociclib
Regulators have stopped a Phase III clinical trial of Pfizer’s Ibrance early after it demonstrated improved survival in women with …
Trial results back NICE decision on Novartis cancer drug
April 15, 2015Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab
Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …
Merck hires life sciences business head
April 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, Merck Millipore, Sigma-Aldrich, udit batra
Merck has confirmed that the current chief executive and president of Merck Millipore Dr Udit Batra has been appointed to lead …
FDA grants AstraZeneca immune drug orphan status
April 15, 2015Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab
The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …
AZ and Takeda diabetes drugs get FDA safety update
April 15, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin
An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
Vetter confirms new managing director
April 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Oliver Albrecht, Vetter
German contract development and manufacturing organisation Vetter has appointed Oliver Albrecht as a managing director. Albrecht replaces Max Horn in …
World Health Organisation calls for full trial transparency
April 14, 2015Research and Development, Sales and Marketing Ben Goldacre, EU, WHO, World Health Organisation, alltrials, clinical trials, sense about science, transparency
The World Health Organization has thrown its weight behind clinical trial transparency in a new statement on its position. WHO …
IBM partners with J&J, Apple and Medtronics ‘to transform healthcare’
April 14, 2015Sales and Marketing Apple, J&J, JJ, ibm, medtronics
IT firm IBM has teamed up with pharma giants and tech companies to expand its presence in the health and …
AstraZeneca partners with PatientsLikeMe
April 14, 2015Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
